北京中医药大学学报
北京中醫藥大學學報
북경중의약대학학보
JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
2001年
3期
55-57
,共3页
邱仲川%赵琳%陈佩%胡琦%曹妹芳%王运律%应平平%杨懿萍%杨红%杨协珍%吴翰香
邱仲川%趙琳%陳珮%鬍琦%曹妹芳%王運律%應平平%楊懿萍%楊紅%楊協珍%吳翰香
구중천%조림%진패%호기%조매방%왕운률%응평평%양의평%양홍%양협진%오한향
补肾复方冲剂%肾阳虚%再生障碍性贫血%造血祖细胞
補腎複方遲劑%腎暘虛%再生障礙性貧血%造血祖細胞
보신복방충제%신양허%재생장애성빈혈%조혈조세포
在探讨补肾复方冲剂治疗肾阳虚型再生障碍性贫血（简称再障）临床疗效基础上，观察其对于再障患者骨髓造血祖细胞影响。以补肾复方冲剂治疗30例，复方皂矾丸、康力龙各治疗15例。采用甲基纤维素培养法观察3组病例治疗前、后骨髓造血祖细胞水平变化，并与正常献血员对照。结果示补肾复方组临床有效率为80%，明显高于复方皂矾丸（40%）与康力龙组（46.67%）；且补肾复方组治疗有效病例的骨髓造血祖细胞（BFU-E及CFU-GM）恢复明显优于复方皂矾丸与康力龙组；3组间无效者骨髓BFU-E及CFU-GM水平无明显变化。说明补肾复方冲剂治疗肾阳虚型再障疗效不仅高于复方皂矾丸和康力龙组，且其有效者血液学恢复更为完全。
在探討補腎複方遲劑治療腎暘虛型再生障礙性貧血（簡稱再障）臨床療效基礎上，觀察其對于再障患者骨髓造血祖細胞影響。以補腎複方遲劑治療30例，複方皂礬汍、康力龍各治療15例。採用甲基纖維素培養法觀察3組病例治療前、後骨髓造血祖細胞水平變化，併與正常獻血員對照。結果示補腎複方組臨床有效率為80%，明顯高于複方皂礬汍（40%）與康力龍組（46.67%）；且補腎複方組治療有效病例的骨髓造血祖細胞（BFU-E及CFU-GM）恢複明顯優于複方皂礬汍與康力龍組；3組間無效者骨髓BFU-E及CFU-GM水平無明顯變化。說明補腎複方遲劑治療腎暘虛型再障療效不僅高于複方皂礬汍和康力龍組，且其有效者血液學恢複更為完全。
재탐토보신복방충제치료신양허형재생장애성빈혈（간칭재장）림상료효기출상，관찰기대우재장환자골수조혈조세포영향。이보신복방충제치료30례，복방조반환、강력룡각치료15례。채용갑기섬유소배양법관찰3조병례치료전、후골수조혈조세포수평변화，병여정상헌혈원대조。결과시보신복방조림상유효솔위80%，명현고우복방조반환（40%）여강력룡조（46.67%）；차보신복방조치료유효병례적골수조혈조세포（BFU-E급CFU-GM）회복명현우우복방조반환여강력룡조；3조간무효자골수BFU-E급CFU-GM수평무명현변화。설명보신복방충제치료신양허형재장료효불부고우복방조반환화강력룡조，차기유효자혈액학회복경위완전。
The study was to observe the effects of Bushen Compound Instant Granules (BCIG) on the bone marrow hematopoietic progenitor cells (BMHPC) in the patients with aplastic anemia of the kidney-yang deficiency type. 30 Cases were treated with BCIG, 15 cases with Compound Zaofan Pills (CZP), and 15 cases with stanozolol; the changes in the levels of BMHPC in the 3 groups were observed before and after the treatment by the methyl cellulose culture method, with a control group consisting of 15 healthy human subjects. The results showed that the clinical effective rate of the BCIG group was 80%, obviously higher than those of the CZP group (40%) and stanozolol group (46.67%); the recovery of the levels of bone marrow BFU-E and CFU-GM in the effective cases in the BCIG group was more obvious than that in the effective cases in the CZP group and stanozolol group; and there were no obvious changes in the levels of bone marrow BFU-E and CFU-GM in the ineffective cases in all the 3 groups. It could be seen from the results that the effective rate of BCIG in treating aplastic anemia of the kidney-yang deficiency type was higher than those of CZP and stanozolol, and the hematological recovery of the patients responding to BCIG was more complete.
